Physician profile
Christopher Puleo
NPI 1942662697
$1,724.93
in general payments reported to CMS, 2019-2025
12 companies · $66.20 in 2025
The $66.20 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $292 · 2021: $723 · 2022: $614 · 2024: $28.88 · 2025: $66.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $286.82 | 2020-2022 | |
| Abbott Laboratories | $247.90 | 2022 | |
| Esperion Therapeutics, INC. | $200.43 | 2020-2021 | |
| Abiomed | $178.49 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $176.42 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $148.92 | 2021-2022 | |
| Medtronic, INC. | $138.97 | 2021-2025 | Micra, Mycarelink, Linq II |
| Pfizer INC. | $118.23 | 2021-2022 | |
| Astellas Pharma US INC | $114.96 | 2021 | |
| Livanova USA, INC. | $55.23 | 2020 | |
| Amgen INC. | $34.76 | 2021 | |
| Boston Scientific Corporation | $23.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Puleo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.